



5.8 billion patient treatment days

With EU approved biosimilar medicines since 2006



+25,000 more UK patients with moderate Rheumatoid arthritis get access to biologic therapy thanks to biosimilar competition



€50 billion

using biosimilar medicines between 2006-2023

in 2023 alone



A growing opportunity for patients with over

110 new biologic medicines opening to biosimilar competition by 2032



A considerable opportunity for European healthcare budget: a \$53.58 N market will open to competition between



By 2028

biosimilars impact

will be >50 %

of the off-patent

competition in Europe



Biosimilar medicines opportunity remains argely untapped with only

14% volume share of the accessible market in Europe



Europe remains the global leader with over 50% of the biosimilar utilisation



5.8 billion patient treatment days

With EU approved biosimilar medicines since 2006



Source: IQVIA Spotlight on Biosimilars in Europe 2021





+25,000 more UK patients with moderate Rheumatoid arthritis get access to biologic therapy thanks to biosimilar competition



Source: NICE UK 2021





A growing opportunity for patients with over 1 1 0 new biologic medicines opening to biosimilar competition by 2032



Source: IQVIA Biosimilars Competition in Europe 2020





A considerable opportunity for European healthcare budget: a \$53.5BN market will open to competition 2024-2032



Source: IQVIA Biosimilars Competition in Europe 2020





biosimilars impact
will be >50%
of the off-patent
competition in Europe




 $Source: filling the gap \ https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines_4b2e9cb9-enger (a) and the gap https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines_4b2e9cb9-enger (a) and the gap https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines_4b2e9cb9-enger (a) and the gap https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines_4b2e9cb9-enger (a) and the gap https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines-migration-health/challen$





Biosimilar medicines opportunity remains largely untapped with only 14% volume share of the accessible market in Europe




Source: IQVIA MIDAS® Q4 2020, IQVIA ForecastLink data for post-2020 period, Rx biologics in 23 European markets





Europe remains the global leader with over 50% of the biosimilar utilisation



Source: IQVIA MIDAS MAT Q1 2021; Rx-only. Figures are in Thousands of USD at Constant Exchange Rate

